| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Sep―10 |
Diagnostic and pharmacological correction of cardiovascular system changes in children, adolescents, and young adults with long COVID: comparative randomized clinical trial in parallel groups |
L. A. Balykova, M. V. Shirmankina, A. V. Krasnopolskaya, A. A. Stradina, S. A. Ivyansky, T. M. Duvayarova, D. S. Rodionov |
| 2 |
[GO] |
2025―Jul―14 |
SARS-CoV-2 Main Protease inhibitors in trace constituents from Algerian herbal medicines using in silico approaches |
B. Yabrir, A. Belhassan, T. Lakhlifi, G. S. Moran, M. Bouachrine, L. G. Candia |
| 3 |
[GO] |
2025―Jul―09 |
Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients |
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva |
| 4 |
[GO] |
2025―Jul―09 |
Prevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus |
A. T. Leinsoo, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, A. V. Kryukov, S. N. Mammaev, et al. (+8) Zh. A. Sozaeva, M. S.-Kh. Sozaeva, K. A. Akmalova, L. Z. Bolieva, A. I. Dobroselskaya, M. L. Maksimov, K. B. Mirzaev, D. A. Sychev |
| 5 |
[GO] |
2023―Aug―09 |
Analysis of cytokine response characteristics and immunopathogenetic effects of double-stranded sodium salt RNA-based drug for postexposure prophylaxis against novel coronavirus infection: double-blind, placebo-controlled trial |
O. A. Radaeva, L. A. Balykova, K. Ya. Zaslavskaya, Yu. A. Kostina, N. A. Pyataev, N. M. Selezneva, et al. (+5) A. V. Klimova, I. Yu. Chegodaeva, K. N. Koryanova, A. V. Taganov, P. A. Bely |
| 6 |
[GO] |
2023―May―02 |
Post-exposure prophylaxis of COVID-19: results of double-blind, placebo-controlled, multicenter clinical study evaluation of efficacy and safety of double-stranded sodium salt RNA drug |
L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, A. V. Taganov, P. A. Bely, K. A. Zakharov, et al. (+9) V. V. Popova, T. I. Chudinovskikh, S. V. Teplykh, I. V. Balaban, R. S. Kozlov, N. V. Kirichenko, E. N. Simakina, K. N. Koryanova, D. Yu. Pushkar |
| 7 |
[GO] |
2023―Feb―15 |
EFFICACY AND SAFETY OF ORIGINAL DRUG BASED ON HEXAPEPTIDE SUCCINATE IN COMPLEX COVID-19 THERAPY IN ADULTS HOSPITALIZED PATIENTS |
L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, P. A. Bely, V. F. Pavelkina, N. A. Pyataev, et al. (+9) A. Yu. Ivanova, G. V. Rodoman, N. E. Kostina, V. B. Filimonov, E. N. Simakina, D. A. Bystritsky, A. S. Agafyina, K. N. Koryanova, D. Yu. Pushkar |
| 8 |
[GO] |
2022―Dec―16 |
CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19 |
E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, et al. (+7) K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon, M. Yu. Samsonov |
| 9 |
[GO] |
2022―Dec―16 |
CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY |
D. N. Zemskov, L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, P. A. Bely, E. V. Semenova, et al. (+2) M. V. Shirmankina, K. N. Koryanova |
| 10 |
[GO] |
2022―Dec―16 |
CONSUMPTION DETAILS OF SYSTEMICALLY ACTING ANTIVIRAL AND ANTIMICROBIAL PREPARATIONS IN PERIOD OF NOVEL CORONAVIRUS INFECTION SPREAD IN RETAIL SECTOR OF SAMARA REGION PHARMACEUTICAL MARKET |
I. K. Petrukhina, P. A. Lebedev, I. I. Sirotko, T. K. Ryazanova, E. P. Gladunova, A. A. Garanin |
| 11 |
[GO] |
2022―Nov―03 |
MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION |
L. A. Balykova, N. M. Selezneva, E. I. Gorshenina, O. I. Shepeleva, N. V. Kirichenko, E. N. Simakina, et al. (+7) K. B. Kolontarev, D. Yu. Pushkar, D. N. Zemskov, K. Ya. Zaslavskaya, S. M. Noskov, A. V. Taganov, P. A. Bely |
| 12 |
[GO] |
2022―Jul―26 |
POLYPHARMACY IN MANAGMENT OF IN-PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19) |
V. I. Petrov, A. Yu. Ryazanova, N. S. Privaltseva, D. A. Nekrasov |
| 13 |
[GO] |
2022―May―12 |
CLINICAL AND ECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICS CONSUMPTION BY PATIENTS WITH COVID-19 |
V. I. Petrov, N. Yu. Ryazanova, A. V. Ponomareva, O. V. Shatalova, Ya. V. Levina |
| 14 |
[GO] |
2022―Mar―11 |
EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 |
L. A. Balykova, K. Ya. Zaslavskaya, V. F. Pavelkina, N. A. Pyataev, N. M. Selezneva, N. V. Kirichenko, et al. (+8) A. Yu. Ivanova, G. V. Rodoman, K. B. Kolontarev, K. S. Skrupsky, E. N. Simakina, O. A. Mubarakshina, A. V. Taganov, D. Yu. Pushkar |
| 15 |
[GO] |
2021―Dec―12 |
STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT |
L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, Yu. A. Kostina, M. S. Iskandyarova, E. V. Negodnova, et al. (+3) V. V. Eremeev, L. F. Sabirov, E. V. Semeleva |
| 16 |
[GO] |
2021―Aug―20 |
GENETIC PREDICTORS OF SEVERITY AND EFFICACY OF COVID-19 PHARMACOTHERAPY |
I. N. Shishimorov, O, V. Magnitskaya, Yu. V. Ponomareva |
| 17 |
[GO] |
2021―May―31 |
MECHANISMS OF CYTOKINE STORM DEVELOPMENT IN COVID-19 AND NEW POTENTIAL TARGETS OF PHARMACOTHERAPY |
V. I. Petrov, A. A. Amosov, A. S. Gerasimenko, O. V. Shatalova, A. V. Ponomareva, A. N. Akinchits, et al. (+2) I. S. Kulakova, V. S. Gorbatenko |
| 18 |
[GO] |
2021―Mar―29 |
EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19) |
L. A. Balykova, V. F. Pavelkina, N. V. Shmyreva, N. A. Pyataev, N. M. Selezneva, O. I. Shepeleva, R. Z. Almyasheva |
| 19 |
[GO] |
2021―Mar―29 |
COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS |
O. V. Zhukova, I. N. Kagramanyan, A. L. Khokhlov |
|
